Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells

Complement inhibitor therapy should be available to patients with paroxysmal nocturnal hemoglobinuria throughout the world.

International journal of hematology·2026

Coinheritance of polymorphic alleles of PIEZO1, G6PD and HBB enhances protection against malaria.

One health (Amsterdam, Netherlands)·2025

Pathogenesis of paroxysmal nocturnal hemoglobinuria.

Blood·2025

How to perform a high-quality peer review.

Clinical hematology international·2025

Pathogenic G6PD variants: Different clinical pictures arise from different missense mutations in the same codon.

British journal of haematology·2024

Plasmodium vivax Malaria and G6PD Testing.

Pathogens (Basel, Switzerland)·2023

Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study.

Blood·2026

Inhibition of nucleoporin 214 depletes leukemia stem cells by promoting heme catabolism and lipid peroxidation.

Blood·2026

International Consensus Criteria for the Diagnosis, Treatment Initiation, and Response Assessment for T-LGL Leukemia.

Blood·2026

Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.

Blood·2026

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Blood·2026

T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.

Blood·2026

[Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Intrathecal immunoglobulin administration for refractory viral central nervous system infection after allogeneic hematopoietic stem cell transplantation].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.

Journal of the American College of Cardiology·2026

Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials.

JAMA·2026

Advanced therapy medicinal products in Saudi Arabia: Regulation and development.

Regenerative therapy·2026

289th ENMC international workshop: assessing and managing emerging AAV related toxicities after gene therapy for neuromuscular disorders, 26 - 28 September 2025, Hoofddorp, The Netherlands.

Neuromuscular disorders : NMD·2026

Related Experiment Videos

Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells

Related Concept Videos

Complement inhibitor therapy should be available to patients with paroxysmal nocturnal hemoglobinuria throughout the world.

Coinheritance of polymorphic alleles of PIEZO1, G6PD and HBB enhances protection against malaria.

Pathogenesis of paroxysmal nocturnal hemoglobinuria.

How to perform a high-quality peer review.

Pathogenic G6PD variants: Different clinical pictures arise from different missense mutations in the same codon.

Plasmodium vivax Malaria and G6PD Testing.

Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study.

Inhibition of nucleoporin 214 depletes leukemia stem cells by promoting heme catabolism and lipid peroxidation.

International Consensus Criteria for the Diagnosis, Treatment Initiation, and Response Assessment for T-LGL Leukemia.

Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.

[Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].

[Intrathecal immunoglobulin administration for refractory viral central nervous system infection after allogeneic hematopoietic stem cell transplantation].

Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.

Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials.

Advanced therapy medicinal products in Saudi Arabia: Regulation and development.

289th ENMC international workshop: assessing and managing emerging AAV related toxicities after gene therapy for neuromuscular disorders, 26 - 28 September 2025, Hoofddorp, The Netherlands.

Related Experiment Videos

Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells

Related Concept Videos

Related Articles